Clinical trials: Anthracyclines
Breast Cancer
Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients
This is an interventional, prospective and monocentric study. This study includes the evaluation before and after (neo)adjuvant therapy of : one group of patients receiving anthracyclines and taxanes a second group of patients…
- Trial name
- PROTECT-03 (NCT04638712)
- Testing
- Microbiopsy sample, Muscle echography, Maximal strength, Body composition, Quality of life and Physical activity level
- Where
- France
- Volunteers
- 13 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Breast Cancer
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
The purpose of this randomized Phase III study is to determine whether preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large…
- Trial name
- Medifocus301 (NCT01204801)
- Testing
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Where
- 2 sites in United States, Canada
- Volunteers
- 238 people
- Sponsor
- Medifocus, Inc.
Cardiotoxicity, Heart Failure
Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines
This is a pilot prospective cohort study, in adult female subjects 18-85 years old with a diagnosis of invasive breast cancer who are planned for anthracycline-inclusive chemotherapy and followed up for a time period of 6 months…
- Conditions
- Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy
- Trial name
- NCT03155802
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stony Brook University
Breast Cancer
Intravenous RPR109881 in Male or Female Patients With Advanced Breast Cancer Who no Longer Respond to Anthracycline, Taxane and Capecitabine Treatment
The purpose of this clinical trial is to determine if the investigational drug is able to reduce/shrink advanced breast cancer tumors in patients who no longer benefit from anthracyclines, taxanes and capecitabine.
- Trial name
- NCT00087958
- Testing
- XRP9881
- Where
- 15 sites in United States, Argentina and 13 more
- Volunteers
- 168 people
- Sponsor
- Sanofi
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Breast Cancer, Metastases
Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)
The purpose of this research study is to assess the response rate of the investigational drug BMS-247550 (Ixabepilone) in women with metastatic breast cancer who are refractory to an anthracycline, a taxane, and capecitabine.
- Trial name
- NCT00080262
- Testing
- Ixabepilone
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 125 people
- Sponsor
- R-Pharm
Anthracycline Related Cardiotoxicity in Breast Cancer
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function.
- Trial name
- NCT03934905
- Testing
- sulforaphane
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Texas Tech University Health Sciences Center
Breast Cancer
Pegylated Liposomal Doxorubicin or Epirubicin in Neoadjuvant or Adjuvant Chemotherapy for Breast Cancer.
Pegylated liposomal doxorubicin or epirubicin in neoadjuvant or adjuvant chemotherapy for breast cancer.
- Trial name
- NCT03983096
- Where
- China
- Volunteers
- 1,213 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences
Breast Neoplasms, Breast Cancer
Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT)
The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast cancer who have failed…
- Trial name
- CAT (NCT01446016)
- Testing
- Paclitaxel, Docetaxel, Abraxane
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- The Methodist Hospital Research Institute
Leukemia
Phase III Trial in Acute Promyelocytic Leukemia Patients
Open label, randomised, phase III multicenter trial.
- Trial name
- APL0406 (NCT00482833)
- Testing
- arsenic trioxide, idarubicin, mercaptopurine
- Where
- 110 sites in Austria, Germany and 1 more
- Volunteers
- 276 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Breast Cancer, Lymphoma, Large B-Cell, Diffuse
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
As the cancer-related prognosis improves thanks to recent advances in cancer-targeted therapies, the prognostic burden of chemotherapy-related complications - including cardiotoxicity - is increasingly recognised.
- Conditions
- Breast Cancer, Lymphoma, Large B-Cell, Diffuse, Cardiotoxicity, Left Ventricular Dysfunction
- Trial name
- CONTROL (NCT05728632)
- Testing
- Nebivolol
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Giulio Stefanini
Breast Cancer
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's…
- Trial name
- NCT00388726
- Testing
- E7389, Physician's Choice
- Where
- 137 sites in United States, Argentina and 15 more
- Volunteers
- 762 people
- Sponsor
- Eisai Inc.
Breast Cancer
A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma
The purpose of this project is to assess the feasibility of collecting plasma samples for cardiac biomarker assessment, and to identify if there is an associations between the biomarkers, echocardiographic features and the…
- Trial name
- OTT14-01 (NCT02156648)
- Testing
- Feasibility study
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ottawa Hospital Research Institute
Childhood Cancer
Cardiac 3D MRI in Pediatric Cancer Patients
This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treatment that…
- Trial name
- NCT02130934
- Testing
- Cardiac 3D MRI
- Where
- 2 sites in United States
- Sponsor
- Majd Makhoul
HER2-positive Breast Cancer
A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
This is a randomized controlled trial of HER-2 positive breast cancer patients treated with lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous anthracycline
- Trial name
- NCT03085368
- Testing
- lapatinib/herceptin
- Where
- China
- Volunteers
- 482 people
- Sponsor
- Peking Union Medical College Hospital
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Breast Cancer
Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines.
- Trial name
- SPRINT (NCT07070765)
- Testing
- Sodium-glucose transport-2 (SGLT-2) inhibitors, Standard medical treatment
- Where
- 2 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- University of Aberdeen
Undifferentiated Pleomorphic Sarcoma (UPS)
SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma
This is a prospective, single-center, single-arm, open-label phase II exploratory study to evaluate the efficacy, safety, and immune remodeling effects of stereotactic body radiotherapy (SBRT) combined with reduced-dose…
- Trial name
- SPARK (NCT07817095)
- Testing
- Toripalimab, Liposomal doxorubicin, Stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital